Dumann H, Meuer S C, Renschin G, Köhler H
I. Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität Mainz, BRD.
Nephron. 1990;55(2):136-40. doi: 10.1159/000185941.
We investigated the influence of thymopentin as an adjuvant for hepatitis B vaccination on in vitro monocyte and T cell function and in vivo antibody response in a prospective, placebo-controlled double-blind trial in 20 low- and nonresponders to hepatitis B vaccination on chronic hemodialysis. 50 mg thymopentin was given subcutaneously twice per week for 3 weeks, followed by 1 intramuscular injection of 40 micrograms HB-Vax and 3 subsequent injections of thymopentin. After 1 month, the patients were boostered with 40 micrograms HB-Vax. There was no significant difference in T cell and monocyte function after administration of thymopentin, as determined in vitro. After 3 months, 3 patients in the placebo and 2 patients in the thymopentin group had antibody titers greater than 10 U/l. In both groups only patients with normal or slightly impaired monocyte function responded to vaccination. Thus, we were not able to demonstrate a beneficial effect of thymopentin on hepatitis B vaccination in nonresponders on chronic hemodialysis. Furthermore, functional tests were not able to identify a subpopulation of uremic nonresponders who would benefit from thymopentin.
在一项针对20名慢性血液透析患者中对乙肝疫苗接种无反应或反应低下者的前瞻性、安慰剂对照双盲试验中，我们研究了胸腺五肽作为乙肝疫苗接种佐剂对体外单核细胞和T细胞功能以及体内抗体反应的影响。每周两次皮下注射50毫克胸腺五肽，共3周，随后肌肉注射1次40微克乙肝疫苗，之后再注射3次胸腺五肽。1个月后，患者用40微克乙肝疫苗加强免疫。体外检测显示，给予胸腺五肽后T细胞和单核细胞功能无显著差异。3个月后，安慰剂组有3名患者、胸腺五肽组有2名患者的抗体滴度大于10 U/l。两组中只有单核细胞功能正常或轻度受损的患者对疫苗接种有反应。因此，我们未能证明胸腺五肽对慢性血液透析无反应者的乙肝疫苗接种有有益作用。此外，功能测试无法识别出能从胸腺五肽中获益的尿毒症无反应者亚群。
